Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 367-377 , September 2010

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

  • Lon S. Schneider

      Affiliations

    • Departments of Psychiatry and Neurology, Keck School of Medicine, and Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 323-442-7600; Fax: 323-442-7601.
    • ,
  • Richard E. Kennedy

      Affiliations

    • School of Public Health, University of Alabama, Birmingham, AL, USA
    • ,
  • Gary R. Cutter

      Affiliations

    • School of Public Health, University of Alabama, Birmingham, AL, USA
    • ,
  • Alzheimer’s Disease Neuroimaging Initiative

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study registration: ClinicalTrials.gov Identifier: NCT00106899.

PII: S1552-5260(10)02192-8

doi: 10.1016/j.jalz.2010.07.004

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 367-377 , September 2010

Article Tools

* Image Usage & Resolution